FundedIQ
Biotechnology Research

Intrinsic Foundries

Intrinsic Foundries is pioneering carbon capture and utilization technology that converts industrial waste streams into valuable biochemicals. Our proprietary microalgae platforms transform CO₂ emissions, thermal waste, and agricultural residues into high-value products including pigments, proteins, and specialty lipids. Founded on the principle that carbon isn’t waste—it’s untapped feedstock—we operate at the intersection of bioprocess engineering, synthetic biology, and sustainable manufacturing.

www.i-foundries.com Boston, United States 11-50 employees
Total raised
$1.3M
Rounds
1
Latest
Seed
Feb 2026

Intrinsic Foundries is pioneering carbon capture and utilization technology that converts industrial waste streams into valuable biochemicals. Our proprietary microalgae platforms transform CO₂ emissions, thermal waste, and agricultural residues into high-value products including pigments, proteins, and specialty lipids. Founded on the principle that carbon isn’t waste—it’s untapped feedstock—we operate at the intersection of bioprocess engineering, synthetic biology, and sustainable manufacturing.

Intrinsic Foundries has raised $1.3M across 1 round. Its most recent round was a Seed of $1.3M in Feb 2026. Full funding history, investors, and team are detailed below.

Funding history

1 round · 1 visible Unlock with plan

1 round on record.

Date
Round
Amount
Lead investor
Feb 17, 2026
Seed
$1.3M

Unlock the lead investor and full details for this round.

Unlock funding history →

People

Unlock with plan

Founders, executives, and decision-makers — sourced and refreshed weekly.

Name
Role
LinkedIn

See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.

Unlock people data →

Intrinsic Foundries is featured in

Similar companies

FibroBiologics

FibroBiologics is a regenerative medicine firm situated in Houston, Texas that is working on an inventive approach to treat chronic diseases using fibroblast cells. Their innovative research spans across several clinical pathways such as Disc Degeneration, Orthopedics, Multiple Sclerosis, and Cancer, and is supported by over 150 U.S. and International patents that have either been issued or are still pending. FibroBiologics' work stands as a testament to the development of cell therapy and represents the future of medical advancement.

Series Unknown $3.0M
Foamlab

FoamLab specializes in high-performance, bio-based foams made from bacterial nanocellulose and develops a new class of sustainable foams made from bacterial cellulose, a natural and renewable material grown through fermentation.

Seed $3.5M
Auxilium Biotechnologies

Auxilium Biotechnologies specializes in developing technology for repairing peripheral nerves.

Series Unknown $3.5M
Expedition Medicines

Expedition Medicine's industry-leading chemoproteomics data generating engine learns the rules of molecular reactivity, enabling programmable small molecule medication design.

Series A $50.0M
Avidicure

Avidicure is leading the way in developing a new type of antibody treatment called "AVC-Boosters", which have dual agonistic capabilities and are engineered for increased avidity. These antibodies are designed to effectively and safely deliver potent monotherapy for cancer treatment, with a wide range of potential uses in the field of oncology.

Seed $50.0M
Orange Grove Bio

Orange Grove Bio (OGB) is a platform that specializes in investing and developing preclinical drugs, with the aim of decreasing the expenses associated with discovering medications and expediting their progression into clinical trials.

Series Unknown $5.1M
Verschuren Centre

The Verschuren Centre assists in the advancement of sustainable technologies for cleantech companies and supports their efforts to enter the market.

Series Unknown $1.0M
Nanite

A new class of programmable polymer nanoparticles is being developed by Nanite, a next-generation non-viral gene delivery business, for a variety of applications and indications. The business' AI-driven SAYER platform combines state-of-the-art, high-throughput experimental and computational methodologies to create delivery systems that are appropriate for their intended use and transport a variety of genetic cargoes with tissue selectivity.

Seed $6.0M
Living Carbon

a nonprofit organisation dedicated to reducing greenhouse gas emissions by genetically increasing CO2 collection and storage in trees

Series A $21.0M
Love Lifesciences

Love Lifesciences is creating a line of injection safety tools that will enhance patient comfort when administering injection drugs. The injection procedure is time-consuming, risky for unneeded pain, and typically causes worry and panic. The current injection approach also leaves a lot of possibility for error in terms of dosage and needle stick injuries. Since the procedure can be so unpleasant, people frequently refuse or stop using these injectable therapy choices. When these issues are present together, patients experience worse health outcomes. Our revised injection process gives patients full injection control while reducing the chance of error. Unnecessary fear, worry, and discomfort shouldn't interfere with patient treatment in any way.

Series Unknown $280k
Empatica

Empatica is a startup that specializes in emotional computing and human data analytics. We create ground-breaking wearable technology with superior medical sensing. Our system consists of a pair of wristbands, software for desktop and smartphone computers, and real-time syncing with a cloud computing service.

Series B
Cybele Microbiome

Cybele utilizes unique technology to deliver high-effective solutions for human health.

Series Unknown $890k
Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.